Drug Profile
Research programme: bone disease therapeutics - Pfizer
Alternative Names: SFRP-1 inhibitorsLatest Information Update: 27 Sep 2011
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Indoles; Small molecules; Sulfonamides
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone disorders
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 16 Apr 2008 Preclinical trials in Bone disorders in USA (PO)